CAR-T

China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)

China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)  #CARTTherapy #Leukemia #ChildhoodCancer #ALL #CART #AcuteLymphoblasticLeukemia #Patientstory China’s CAR-T cell therapy is emerging as a beacon of hope in the fight against cancer, bringing unprecedented treatment possibilities. As a precise cellular immunotherapy, CAR-T therapy enhances the cancer-fighting abilities of T-cells through genetic editing technology, Read More

November 1st,2024 Leukemia , CAR-T , patient story

China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients

**China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients** #CAR-TTherapy #MultipleMyeloma #PatientStory #CancerSurvivor In recent years, CAR-T cell therapy in China has spearheaded a revolution in hematologic cancer treatment. This innovative immunotherapy has brought a glimmer of hope to many patients, especially those with relapsed and refractory cases who Read More

October 31st,2024 Myeloma , CAR-T

China’s CSPC Pharmaceutical Group CAR-T Therapy: Targeted Treatment for Myasthenia Gravis

China’s CSPC Pharmaceutical Group CAR-T Therapy: Targeted Treatment for Myasthenia Gravis #CARTTherapy #MyastheniaGravis #ChinaPharma #CSPC #CART China’s CAR-T cell therapies are attracting international attention. Recently, CSPC Pharmaceutical Group secured another clinical trial approval for a CAR-T therapy, marking a significant milestone in the treatment of autoimmune diseases. China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) officially Read More

October 31st,2024 CAR-T

China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)

**China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)** #CLL1CART #AML #Leukemia #CART #CARTtherapy #AcuteMyeloidLeukemia #CLL1 #CD371 In recent years, China’s rise in the field of medical innovation has been remarkable, especially with breakthroughs in cancer and hematologic malignancy treatments that are drawing global attention. Today, we are introducing a cutting-edge treatment from China—donor-derived CLL-1 Read More

October 29th,2024 Leukemia , CAR-T

Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma(DLBCL) Patient Achieve Complete Remission

### Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma Patient Achieve Complete Remission #CAR-T #CancerTreatment #Lymphoma #DLBCL #PrecisionMedicine In an inspiring treatment case, a 38-year-old Chinese male patient with TP53-deficient Diffuse Large B-cell Lymphoma (DLBCL) achieved complete remission through Chinese CAR-T cell therapy. This remarkable outcome has sparked excitement about Read More

October 29th,2024 Lymphoma , CAR-T

Chinese Scientists Achieve Major Breakthrough in Enhancing CAR-T Cell Efficacy: MEK Inhibitors Effectively Prevent CAR-T Cell Exhaustion

Chinese Scientists Achieve Major Breakthrough in Enhancing CAR-T Cell Efficacy: MEK Inhibitors Effectively Prevent CAR-T Cell Exhaustion #CARTCellTherapy #MEKInhibitors #CancerResearch #ChineseScientists #CART #MEK In recent years, CAR-T cell therapy has shown remarkable effectiveness in treating relapsed or refractory B-cell malignancies, particularly in cases where targeted therapies have failed. However, CAR-T therapy’s long-term effectiveness is often limited Read More

October 29th,2024 CAR-T

Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia

### Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia #ALL #CAR-Ttherapy #Leukemia #CancerResearch #B_ALL #LeukemiaTreatment Recently, a Chinese medical team published a notable study titled “Five-year outcome of CD19 combined with CD22 CAR-T cell therapy in B-ALL patients relapsed after allo-transplantation.” The research highlights Read More

October 28th,2024 Leukemia , CAR-T

China’s CAR-T Technology Leads the World: A Miraculous Recovery Journey for Children with systemic lupus erythematosus (SLE)

**China’s CAR-T Technology Leads the World: A Miraculous Recovery Journey for Children with systemic lupus erythematosus (SLE)** #SLE #lupus #systemiclupuserythematosus #CAR_Ttherapy #CancerSurvivor #ChineseHealthcare#PatientStory In the field of medicine, the boundary between science and miracles is often blurred. This October, news from Zhejiang, China, shocked the world: 20 children suffering from refractory systemic lupus erythematosus (SLE) Read More

October 28th,2024 CAR-T

Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia(ALL) with a 100% Response Rate!

Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia with a 100% Response Rate! #ALL #AcuteLymphoblasticLeukemia #Leukemia #CART #CARTtherapy In recent years, CAR-T cell therapies from China have garnered global attention in the fight against cancer, and now another CAR-T product is about to hit the market. Priscabtagene Autoleucel Injection Read More

October 25th,2024 Leukemia , CAR-T

How to Choose Among Similar CAR-T Therapies?

**How to Choose Among Similar CAR-T Therapies?** Currently, there are multiple CAR-T products targeting the same antigen available on the market, which can make it difficult for patients to decide which one to choose. Experts recommend selecting a therapy based on the treatment target. It is generally advisable to prioritize approved products, as they have Read More

October 24th,2024 CAR-T

A 62-Year-Old Leukemia Patient in China Receives CAR-T Therapy, Discharged After One Month, and Still Healthy After Five Years!

A 62-Year-Old Leukemia Patient in China Receives CAR-T Therapy, Discharged After One Month, and Still Healthy After Five Years! #Leukemia #CAR_Therapy #CancerSurvivor #ChineseHealthcare#PatientStory Acute lymphoblastic leukemia (ALL) is a type of leukemia that originates from B or T lymphoid progenitor cells. Leukemia cells proliferate abnormally in the bone marrow, suppressing normal hematopoiesis, leading to anemia, thrombocytopenia, and Read More

October 24th,2024 patient story , CAR-T

What Kind of Multiple Myeloma Patients Are Suitable for CAR-T Therapy in China?

# What Kind of Multiple Myeloma Patients Are Suitable for CAR-T Therapy in China? #MultipleMyeloma #CAR_Therapy #MM #CART #RRMM #Hematology **Multiple Myeloma** (MM) is a malignant hematological disease that affects plasma cells. In recent years, various drugs and treatment methods, such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplantation, have significantly improved the Read More

October 24th,2024 Myeloma , CAR-T